Potential Biomolecules and Current Treatment Technologies for Diabetic Foot Ulcer: An Overview

Author(s): Zenith Khashim, Shila Samuel, Nallusamy Duraisamy, Kathiravan Krishnan*

Journal Name: Current Diabetes Reviews

Volume 15 , Issue 1 , 2019

Become EABM
Become Reviewer

Abstract:

Background: Diabetic foot ulceration remains a major challenge and is one of the most expensive and leading causes of major and minor amputations among patients with diabetic foot ulcer. Hence the purpose of this review is to emphasize on potential molecular markers involved in diabetic foot ulcer physiology, the efficacy of different types of dressing materials, adjunct therapy and newer therapeutic approach like nanoparticles for the treatment of diabetic foot ulcer.

Methods: We conducted a systematic literature review search by using Pubmed and other web searches. The quality evidence of diabetic foot ulcer biomolecules and treatments was collected, summarized and compared with other studies.

Results: The present investigation suggested that impaired wound healing in diabetic patients is an influence of several factors. All the advanced therapies and foot ulcer dressing materials are not suitable for all types of diabetic foot ulcers, however more prospective follow ups and in vivo and in vitro studies are needed to draw certain conclusion. Several critical wound biomolecules have been identified and are in need to be investigated in diabetic foot ulcers. The application of biocompatible nanoparticles holds a promising approach for designing dressing materials for the treatment of diabetic foot ulcer.

Conclusion: Understanding the cellular and molecular events and identifying the appropriate treatment strategies for different foot ulcer grades will reduce recurrence of foot ulcer and lower limb amputation.

Keywords: Diabetic foot ulcer, biomolecules, foot ulcer dressing materials, adjunct therapy, nanoparticles, inflammatory.

[1]
Shahbazian H, Yazdanpanah L, Latifi SM. Risk assessment of patients with diabetes for foot ulcers according to risk classification consensus of International Working Group on Diabetic Foot (IWGDF). Pak J Med Sci 2013; 29(3): 730-4.
[2]
Ramachandran A, Snehalatha C, Shetty AS, Nanditha A. Trends in prevalence of diabetes in Asian countries. W J Diab 2012; 3(6): 110-7.
[3]
Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87(1): 4-14.
[4]
Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011; 94(3): 311-21.
[5]
Aalaa M, Malazy OT, Sanjari M, Peimani M, Mohajeri-Tehrani M. Nurses’ role in diabetic foot prevention and care; a review. J Diabetes Metab Disord 2012; 11(1): 24.
[6]
Fard AS, Esmaelzadeh M, Larijani B. Assessment and treatment of diabetic foot ulcer. Int J Clin Pract Suppl 2007; 61(11): 1931-8.
[7]
Snyder RJ, Hanft JR. Diabetic foot ulcers--effects on QOL, costs, and mortality and the role of standard wound care and advanced-care therapies. Ostomy Wound Manage 2009; 55(11): 28-38.
[8]
Richard JL, Schuldiner S. Epidemiology of diabetic foot problems. La Rev Med Int 2008; 29(Suppl. 2): S222-30.
[9]
Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Phys Rev 2003; 83(3): 835-70.
[10]
Rigo C, Ferroni L, Tocco I, et al. Active silver nanoparticles for wound healing. Int J Mol Sci 2013; 14(3): 4817-40.
[11]
Tsourdi E, Barthel A, Rietzsch H, Reichel A, Bornstein SR. Current aspects in the pathophysiology and treatment of chronic wounds in diabetes mellitus. BioMed Res Int 2013; 2013: 385641.
[12]
Olivera Stojadinovic IP, Katherine A. Gordon, Marjana Tomic-Canic Physiology and pathophysiology of wound healing in diabetes. Third Edition . Med Surg Manage 2012; pp. 127-49.
[13]
Brem H, Jacobs T, Vileikyte L, et al. Wound-healing protocols for diabetic foot and pressure ulcers. Surg Technol Int 2003; 11: 85-92.
[14]
Bowering CK. Diabetic foot ulcers. Pathophysiology, assessment, and therapy. Can Fam Phys 2001; 47: 1007-16.
[15]
Bonham PA. Assessment and management of patients with venous, arterial, and diabetic/neuropathic lower extremity wounds. AACN Clin Issues 2003; 14(4): 442-56.
[16]
Grey JE, Harding KG, Enoch S. Venous and arterial leg ulcersClin Res Ed. 2006; 332: pp. (7537)347-50.
[17]
Eming SA, Krieg T, Davidson JM. Inflammation in wound repair: molecular and cellular mechanisms. J Inv Derm 2007; 127(3): 514-25.
[18]
Edwards R, Harding KG. Bacteria and wound healing. Curr opinInfec Dis 2004; 17(2): 91-6.
[19]
Wolcott RD, Rhoads DD, Dowd SE. Biofilms and chronic wound inflammation. J Wound Care 2008; 17(8): 333-41.
[20]
Boulton AJ. The Diabetic Foot. J Med 2012; 30(2): 36-40.
[21]
Aguilar RF, Terán Soto JM. Jorge Escobedo de la Peña The pathogenesis of the diabetic foot ulcer: prevention and management. Glob Per Diab Foot Ulc 2011.
[22]
Falanga V. Wound healing and its impairment in the diabetic foot. Lancet 2005; 366(9498): 1736-43.
[23]
Walker NI, Harmon BV, Gobe GC, Kerr JF. Patterns of cell death. Met Ach Exp Pat 1988; 13: 18-54.
[24]
Hennessey PJ, Ford EG, Black CT, Andrassy RJ. Wound collagenase activity correlates directly with collagen glycosylation in diabetic rats. J Ped Sur 1990; 25(1): 75-8.
[25]
Jaap AJ, Shore AC, Stockman AJ, Tooke JE. Skin capillary density in subjects with impaired glucose tolerance and patients with type 2 diabetes. Diabet Med 1996; 13(2): 160-4.
[26]
Griffith OW, Stuehr DJ. Nitric oxide synthases: properties and catalytic mechanism. Ann Rev Phy 1995; 57: 707-36.
[27]
Luo JD, Wang YY, Fu WL, Wu J, Chen AF. Gene therapy of endothelial nitric oxide synthase and manganese superoxide dismutase restores delayed wound healing in type 1 diabetic mice. Circ J 2004; 110(16): 2484-93.
[28]
Lee PC, Salyapongse AN, Bragdon GA, et al. Impaired wound healing and angiogenesis in eNOS-deficient mice. Am J Phys 1999; 277(4): H1600-8.
[29]
Wetzler C, Kampfer H, Stallmeyer B, Pfeilschifter J, Frank S. Large and sustained induction of chemokines during impaired wound healing in the genetically diabetic mouse: prolonged persistence of neutrophils and macrophages during the late phase of repair. J Inv Der 2000; 115(2): 245-53.
[30]
Yamasaki K, Edington HD, McClosky C, et al. Reversal of impaired wound repair in iNOS-deficient mice by topical adenoviral-mediated iNOS gene transfer. J Cli Inv 1998; 101(5): 967-71.
[31]
Stallmeyer B, Anhold M, Wetzler C, Kahlina K, Pfeilschifter J, Frank S. Regulation of eNOS in normal and diabetes-impaired skin repair: implications for tissue regeneration. Nit Ox Bio Chem 2002; 6(2): 168-77.
[32]
Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound repair and regeneration. Wound Repair Regen 1999; 7(5): 335-46.
[33]
Amoli MM, Hasani-Ranjbar S, Roohipour N, et al. VEGF gene polymorphism association with diabetic foot ulcer. Diab Res Cli Prac 2011; 93(2): 215-9.
[34]
Rico T, Green J, Kirsner RS. Vascular endothelial growth factor delivery via gene therapy for diabetic wounds: first steps. J Inv Der 2009; 129(9): 2084.
[35]
Yan X, Chen B, Lin Y, et al. Acceleration of diabetic wound healing by collagen-binding vascular endothelial growth factor in diabetic rat model. Diab Res Cli Pra 2010; 90(1): 66-72.
[36]
Presta M, Dell’Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cyt Gro Fac Rev 2005; 16(2): 159-78.
[37]
Okumura M, Okuda T, Nakamura T, Yajima M. Effect of basic fibroblast growth factor on wound healing in healing-impaired animal models. Arzneimittelforschung 1996; 46(5): 547-51.
[38]
Richard JL, Parer-Richard C, Daures JP, et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. A pilot, randomized, double-blind, placebo-controlled study. Diab Car 1995; 18(1): 64-9.
[39]
Young MJL. J.; Knowles, A.; Parnell, L.; Ward, J.D. The treatment of diabetic neuropathic foot ulcers with biosynthetic platelet derived growth factor. Dia Med 1992; 9: s42.
[40]
Aloe L. Nerve growth factor, human skin ulcers and vascularization. Our experience. Prog Brain Res 2004; 146: 515-22.
[41]
Raychaudhuri SK, Raychaudhuri SP, Weltman H, Farber EM. Effect of nerve growth factor on endothelial cell biology: proliferation and adherence molecule expression on human dermal microvascular endothelial cells. Arch Dermatol Res 2001; 293(6): 291-5.
[42]
Matsuda H, Koyama H, Sato H, et al. Role of nerve growth factor in cutaneous wound healing: accelerating effects in normal and healing-impaired diabetic mice. J Exp Med 1998; 187(3): 297-306.
[43]
Generini S, Tuveri MA, Matucci Cerinic M, Mastinu F, Manni L, Aloe L. Topical application of nerve growth factor in human diabetic foot ulcers. A study of three cases. Exp Clin Endocrinol Diabetes 2004; 112(9): 542-4.
[44]
Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen 2008; 16(5): 585-601.
[45]
Tiaka EK, Papanas N, Manolakis AC, Georgiadis GS. Epidermal growth factor in the treatment of diabetic foot ulcers: an update. Per Vas Sur End Ther 2012; 24(1): 37-44.
[46]
Tsang MW, Wong WK, Hung CS, et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care 2003; 26(6): 1856-61.
[47]
Ma C, Hernandez MA, Kirkpatrick VE, Liang LJ, Nouvong AL, Gordon II. Topical platelet-derived growth factor vs. placebo therapy of diabetic foot ulcers offloaded with windowed casts: a randomized, controlled trial. Wounds: Comp Cli Res Prac 2015; 27(4): 83-91.
[48]
Mustoe TA, Pierce GF, Morishima C, Deuel TF. Growth factor-induced acceleration of tissue repair through direct and inductive activities in a rabbit dermal ulcer model. J Cli Inv 1991; 87(2): 694-703.
[49]
Rachfal AW, Brigstock DR. Structural and functional properties of CCN proteins. Vitam Horm 2005; 70: 69-103.
[50]
LeGrand EK. Preclinical promise of becaplermin (rhPDGF-BB) in wound healing. Ame J Sur 1998. 176(2A Suppl): 48s-54s
[51]
Nareika A, Sundararaj KP, Im YB, Game BA, Lopes-Virella MF, Huang Y. High glucose and interferon gamma synergistically stimulate MMP-1 expression in U937 macrophages by increasing transcription factor STAT1 activity. J Ather 2009; 202(2): 363-71.
[52]
Yang Q, Xie RJ, Yang T, et al. Transforming growth factor-beta1 and Smad4 signaling pathway down-regulates renal extracellular matrix degradation in diabetic rats. Chin Med Sci J 2007; 22(4): 243-9.
[53]
Lobmann R, Zemlin C, Motzkau M, Reschke K, Lehnert H. Expression of matrix metalloproteinases and growth factors in diabetic foot wounds treated with a protease absorbent dressing. J Diab Comp 2006; 20(5): 329-35.
[54]
Ladwig GP, Robson MC, Liu R, Kuhn MA, Muir DF, Schultz GS. Ratios of activated matrix metalloproteinase-9 to tissue inhibitor of matrix metalloproteinase-1 in wound fluids are inversely correlated with healing of pressure ulcers. Wound repair and regeneration. Wound Repair Regen 2002; 10(1): 26-37.
[55]
Julie SSB. K. Study on matrix metalloproteinase in diabetic foot ulcer disease. J Biom Pharm Res 2015; 3(4): 56-65.
[56]
Hamada T, Fondevila C, Busuttil RW, Coito AJ. Metalloproteinase-9 deficiency protects against hepatic ischemia/reperfusion injury. J Hepatol 2008; 47(1): 186-98.
[57]
Khandoga A, Kessler JS, Hanschen M, Khandoga AG, Burggraf D, Reichel C, et al. Matrix metalloproteinase-9 promotes neutrophil and T cell recruitment and migration in the postischemic liver. J Leu Bio 2006; 79(6): 1295-305.
[58]
Beaujouin M, Baghdiguian S, Glondu-Lassis M, Berchem G, Liaudet-Coopman E. Overexpression of both catalytically active and -inactive cathepsin D by cancer cells enhances apoptosis-dependent chemo-sensitivity. J Oncogene 2006; 25(13): 1967-73.
[59]
Palka J, Sobolewski K, Bankowski E. Cathepsin D inhibitor from potato reverses inhibition of collagen biosynthesis in wounded skin of rats with experimental diabetes. Acta Biochim Pol 1991; 38(1): 115-8.
[60]
Ahmad J, Zubair M, Malik A, Siddiqui MA, Wangnoo SK. Cathepsin-D, adiponectin, TNF-alpha, IL-6 and hsCRP plasma levels in subjects with diabetic foot and possible correlation with clinical variables: a multicentric study. J Foot 2012; 22(3): 194-9.
[61]
Lauer G, Sollberg S, Cole M, Flamme I, Sturzebecher J, Mann K, et al. Expression and proteolysis of vascular endothelial growth factor is increased in chronic wounds. J Inv Derm 2000; 115(1): 12-8.
[62]
Abbott RE, Corral CJ, MacIvor DM, Lin X, Ley TJ, Mustoe TA. Augmented inflammatory responses and altered wound healing in cathepsin G-deficient mice. Arch Surg 1998; 133(9): 1002-6.
[63]
Bangalore N, Travis J, Onunka VC, Pohl J, Shafer WM. Identification of the primary antimicrobial domains in human neutrophil cathepsin G. J Biochem 1990; 265(23): 13584-8.
[64]
Jeandrot A, Richard JL, Combescure C, et al. Serum procalcitonin and C-reactive protein concentrations to distinguish mildly infected from non-infected diabetic foot ulcers: a pilot study. Diabetologia J 2008; 51(2): 347-52.
[65]
Uzun G, Solmazgul E, Curuksulu H, et al. Procalcitonin as a diagnostic aid in diabetic foot infections. Tohoku J Exp Med 2007; 213(4): 305-12.
[66]
Massara M, De Caridi G, Serra R, et al. The role of procalcitonin as a marker of diabetic foot ulcer infection. Int Wound J 2017; 14(1): 31-4.
[67]
Jozic I, Daunert S, Tomic-Canic M, Pastar I. Nanoparticles for fidgety cell movement and enhanced wound healing. J Inv Derm 2015; 135(9): 2151-3.
[68]
Mukherjee S, Diaz Valencia JD, Stewman S, et al. Human Fidgetin is a microtubule severing the enzyme and minus-end depolymerase that regulates mitosis. J Cel Cyc 2012; 11(12): 2359-66.
[69]
Charafeddine RA, Makdisi J, Schairer D, et al. Fidgetin-Like 2: A Microtubule-Based Regulator of Wound Healing. J Inv Derm 2015; 135(9): 2309-18.
[70]
Bruhn-Olszewska B, Korzon-Burakowska A, Gabig-Ciminska M, Olszewski P, Wegrzyn A, Jakobkiewicz-Banecka J. Molecular factors involved in the development of diabetic foot syndrome. Acta Biochim Pol 2012; 59(4): 507-13.
[71]
Bermudez DM, Xu J, Herdrich BJ, Radu A, Mitchell ME, Liechty KW. Inhibition of stromal cell-derived factor-1alpha further impairs diabetic wound healing. J Vasc Surg 2011; 53(3): 774-84.
[72]
Brown DL, Kane CD, Chernausek SD, Greenhalgh DG. Differential expression and localization of insulin-like growth factors I and II in cutaneous wounds of diabetic and nondiabetic mice. Am J Pathol 1997; 151(3): 715-24.
[73]
Yu DH, Mace KA, Hansen SL, Boudreau N, Young DM. Effects of decreased insulin-like growth factor-1 stimulation on hypoxia inducible factor 1-alpha protein synthesis and function during cutaneous repair in diabetic mice. Wound repair and regeneration. Wound Heal Soc Eur Tiss Rep Soc 2007; 15(5): 628-35.
[74]
Catrina SB, Okamoto K, Pereira T, Brismar K, Poellinger L. Hyperglycemia regulates hypoxia-inducible factor-1alpha protein stability and function J Diab . 2004; 53(12): 3226-32.
[75]
AboElAsrar MA, Elbarbary NS, Elshennawy DE, Omar AM. Insulin-like growth factor-1 cytokines cross-talk in type 1 diabetes mellitus: relationship to microvascular complications and bone mineral density. Cytok J 2012; 59(1): 86-93.
[76]
ALoomans CJ, de Koning EJ, Staal FJ, et al. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes Diab J 2004; 53(1): 195-9.
[77]
Kopp HG, Ramos CA, Rafii S. Contribution of endothelial progenitors and proangiogenic hematopoietic cells to vascularization of tumor and ischemic tissue. Curr Opi Hem 2006; 13(3): 175-81.
[78]
Barcelos LS, Duplaa C, Krankel N, Graiani G, Invernici G, Katare R, et al. Human CD133+ progenitor cells promote the healing of diabetic ischemic ulcers by paracrine stimulation of angiogenesis and activation of Wnt signaling. Circ Res 2009; 104(9): 1095-102.
[79]
Fisken RA, Digby M. Which dressing for diabetic foot ulcers? J Br Podiatr Med 1997; 52(20-22)
[80]
Foster AVM, Spencer S, Edmonds ME. Deterioration of diabetic foot lesions under hydrocolloid dressings. Pact Diab Int 1997; 14(2)
[81]
Lithner F. Adverse effects on diabetic foot ulcers of highly adhesive hydrocolloid occlusive dressing. Diabetes Care 1990; 13(7): 814-5.
[82]
D. M.An investigation into the effects of Intrasite Gel on the in-vitro proliferation of aerobic and anaerobic bacteria [poster].In: Proceedings of 2nd Eur Conf Adv Wound Manage Lond. 1993-207.
[83]
Cazzaniga ALM. D.A.; Mertz, P.M. In: Proceedings of the 5th annual Symposium, (New Orleans). The effect of calcium alginate dressing on the multiplication of bacterial pathogens in vitro. Adv Wound Care 1992-132.
[84]
Lansdown AB. Silver. In: Its antibacterial properties and mechanism of action. J Wound Care 2002; 11(4): 125-30.
[85]
Wright JB, Lam K, Burrell RE. Wound management in an era of increasing bacterial antibiotic resistance: a role for topical silver treatment. Ame J inf Cont 1998; 26(6): 572-7.
[86]
Basterzi Y, Ersoz G, Sarac G, Sari A, Demirkan F. In-vitro comparison of antimicrobial efficacy of various wound dressing materials. Wounds Comp Cli Res Prac 2010; 22(7): 165-70.
[87]
] Balin AK, Pratt L. Dilute povidone-iodine solutions inhibit human skin fibroblast growth. Dermatologic surgery : official publication for Ame Soc Derm Surg 2002; 28(3): 210-4.
[88]
Damour O, Hua SZ, Lasne F, Villain M, Rousselle P, Collombel C. Cytotoxicity evaluation of antiseptics and antibiotics on cultured human fibroblasts and keratinocytes. J Inte Soc Burn Inj 1992; 18(6): 479-85.
[89]
Hilton JR, Williams DT, Beuker B, Miller DR, Harding KG.Wound dressings in diabetic foot disease. Clinical infectious diseases: an official publication of the Inf Dis Soc Ame 2004; 39(6) Suppl 2: S100-3.
[90]
Cullen B, Watt PW, Lundqvist C, et al. The role of oxidised regenerated cellulose/collagen in chronic wound repair and its potential mechanism of action. Int J Biochem Cell Biol 2002; 34(12): 1544-56.
[91]
Patti JM, Boles JO, Hook M. Identification and biochemical characterization of the ligand binding domain of the collagen adhesin from Staphylococcus aureus. J Biochem 1993; 32(42): 11428-35.
[92]
Costa Almeida CE. Collagen implant with gentamicin sulphate as an option to treat a neuroischaemic diabetic foot ulcer: Case report. Int J Surg Case Rep 2016; 21: 48-51.
[93]
Berlanga J, Fernandez JI, Lopez E, et al. Heberprot-P: a novel product for treating advanced diabetic foot ulcer. MEDICC Rev 2013; 15(1): 11-5.
[94]
Fernandez-Montequin JI, Betancourt BY, Leyva-Gonzalez G, et al. Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic foot ulcer: treatment up to complete wound closure. Intl wound J 2009; 6(1): 67-72.
[95]
Pai-Dhungat JV, Falguni, P. Diabetic Foot and Heberprot-P. J Assphy Ind 2014; 62
[96]
Fang RC, Galiano RD. A review of becaplermin gel in the treatment of diabetic neuropathic foot ulcers. Biologics J 2008; 2(1): 1-12.
[97]
Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group. J Vasc Surg 1995; 21(1): 71-8.
[98]
PA D’Hemecourt JS,Karim MR. Sodium carboxymethylcellulose aqueous-based gel vs. becaplermin gel in patients with nonhealing lower extremity diabetic ulcers. Wounds J 1998; 10: 69-75.
[99]
Fernandez-Montequin JI, Infante-Cristia E, Valenzuela-Silva C, et al. Intralesional injections of Citoprot-P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. Int Wound J 2007; 4(4): 333-43.
[100]
Acosta JB, Savigne W, Valdez C, et al. Epidermal growth factor intralesional infiltrations can prevent amputation in patients with advanced diabetic foot wounds. Int Wound J 2006; 3(3): 232-9.
[101]
Mohan VK. Recombinant human epidermal growth factor (REGEN-D 150): effect on healing of diabetic foot ulcers. Diab Res Cli Pra 2007; 78(3): 405-11.
[102]
Viswanathan; V, Pendsey; S, Sekar; N. A Phase III Study to Evaluate the Safety and Efficacy of Recombinant Human Epidermal Growth Factor (REGEN-D™ 150) in Healing Diabetes Wounds. Comp Clin Res Prac 2006; 18(7): 186-96.
[103]
Papanas N, Maltezos E. Growth factors in the treatment of diabetic foot ulcers: new technologies, any promises? Int J low Extm wounds. 2007; 6(1): 37-53.
[104]
Jaiswal SS, Gambhir RP, Agrawal A, Harish S. Efficacy of topical recombinant human platelet derived growth factor on wound healing in patients with chronic diabetic lower limb ulcers. Indian J Surg 2010; 72(1): 27-31.
[105]
Parcells JP, Mileski JP, Gnagy FT, Haragan AF, Mileski WJ. Using antimicrobial solution for irrigation in appendicitis to lower surgical site infection rates. Am J Surg 2009; 198(6): 875-80.
[106]
Heling I, Rotstein I, Dinur T, Szwec-Levine Y, Steinberg D. Bactericidal and cytotoxic effects of sodium hypochlorite and sodium dichloroisocyanurate solutions in vitro. J Endod 2001; 27(4): 278-80.
[107]
Mohamed H, Salma MA, Al Lenjawi B, et al. The efficacy and safety of natural honey on the healing of foot ulcers: a case series. Wounds. Comp Clin Res Prac 2015; 27(4): 103-14.
[108]
Molan P. Not all honeys are the same for wound healing. Eur Tiss Rep Soc Bull 2002; 9(1): 5-6.
[109]
Du Toit DF, Page BJ. An in vitro evaluation of the cell toxicity of honey and silver dressings. J Wound Care 2009; 18(9): 383-9.
[110]
Barnes RC. Point: hyperbaric oxygen is beneficial for diabetic foot wounds. Clin Infect Dis 2006; 43(2): 188-92.
[111]
Cimsit M, Uzun G, Yildiz S. Hyperbaric oxygen therapy as an anti-infective agent. Expert Rev Anti Infect Ther 2009; 7(8): 1015-26.
[112]
Kessler L, Bilbault P, Ortega F, et al. Hyperbaric oxygenation accelerates the healing rate of nonischemic chronic diabetic foot ulcers: a prospective randomized study. Diab Ccare 2003; 26(8): 2378-82.
[113]
Blume PA, Walters J, Payne W, Ayala J, Lantis J. Comparison of negative pressure wound therapy using vacuum-assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomized controlled trial. Diabetes Care 2008; 31(4): 631-6.
[114]
Löndahl M. Hyperbaric oxygen therapy as adjunctive treatment for diabetic foot ulcers. Int J Low Extrem Wounds 2013; 12(2): 152-7.
[115]
Abidia A, Laden G, Kuhan G, et al. The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double-blind randomised-controlled trial. J Eur Soc Vas Surg 2003; 25(6): 513-8.
[116]
Duzgun AP, Satir HZ, Ozozan O, Saylam B, Kulah B, Coskun F. Effect of hyperbaric oxygen therapy on healing of diabetic foot ulcers. J Foot Ankle Surg 2008; 47(6): 515-9.
[117]
Armstrong DG, Lavery LA. Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial. Lancet 2005; 366(9498): 1704-10.
[118]
Dumville JC, Hinchliffe RJ, Cullum N, et al. Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus. Coch Dat Syst Rev 2013; 10: Cd010318.
[119]
Aicher A, Heeschen C, Sasaki K, Urbich C, Zeiher AM, Dimmeler S. Low-energy shock wave for enhancing recruitment of endothelial progenitor cells: a new modality to increase efficacy of cell therapy in chronic hind limb ischemia. Circ J 2006; 114(25): 2823-30.
[120]
Yan X, Zeng B, Chai Y, Luo C, Li X. Improvement of blood flow, expression of nitric oxide, and vascular endothelial growth factor by low-energy shockwave therapy in random-pattern skin flap model. Ann Plast Surg 2008; 61(6): 646-53.
[121]
Moretti B, Notarnicola A, Maggio G, et al. The management of neuropathic ulcers of the foot in diabetes by shock wave therapy. BMC Mus Dis 2009; 10: 54.
[122]
Saggini R, Figus A, Troccola A, Cocco V, Saggini A, Scuderi N. Extracorporeal shock wave therapy for management of chronic ulcers in the lower extremities. Ultr Med Bio 2008; 34(8): 1261-71.
[123]
Furia JP, Rompe JD, Maffulli N. Low-energy extracorporeal shock wave therapy as a treatment for greater trochanteric pain syndrome. Am J Sports Med 2009; 37(9): 1806-13.
[124]
Sherman RA. Maggot therapy for treating diabetic foot ulcers unresponsive to conventional therapy. Diabetes Care 2003; 26(2): 446-51.
[125]
Paul AG, Ahmad NW, Lee HL, et al. Maggot debridement therapy with Lucilia cuprina: a comparison with conventional debridement in diabetic foot ulcers. Int Wound J 2009; 6(1): 39-46.
[126]
Sherman RA, Wyle F, Vulpe M. Maggot therapy for treating pressure ulcers in spinal cord injury patients. J Apil Cord Med 1995; 18(2): 71-4.
[127]
Kashef N, Esmaeeli Djavid G, Siroosy M, Taghi Khani A, Hesami Zokai F, Fateh M. Photodynamic inactivation of drug-resistant bacteria isolated from diabetic foot ulcers. Iran J Microbiol 2011; 3(1): 36-41.
[128]
Bisland SK, Chien C, Wilson BC, Burch S. Pre-clinical in vitro and in vivo studies to examine the potential use of photodynamic therapy in the treatment of osteomyelitis. Photochem Photobiol Sci 2006; 5(1): 31-8.
[129]
Goto B, Iriuchishima T, Horaguchi T, et al. Therapeutic effect of photodynamic therapy using Na-pheophorbide a on osteomyelitis models in rats. Phot Las Surg 2011; 29(3): 183-9.
[130]
Tardivo JP, Baptista MS. Treatment of osteomyelitis in the feet of diabetic patients by photodynamic antimicrobial chemotherapy. Photomed Laser Surg 2009; 27(1): 145-50.
[131]
Tardivo JP, Adami F, Correa JA, Pinhal MA, Baptista MS. A clinical trial testing the efficacy of PDT in preventing amputation in diabetic patients. Phot Phot Ther 2014; 11(3): 342-50.
[132]
Gutiérrez AA. The science behind stable, super-oxidized water: Exploring the various applications of super-oxidized solutions. Wounds: Comp Cli Res Pract 2006; 18(1): 7-10.
[133]
Miranda-Altamirano A. Reducing bacterial infectious complications from burn wounds. A look at the use of Oculus Microcyn60 to treat wounds in Mexico. Wounds: Comp Cli Res Pract 2006; 18(1): 17-9.
[134]
Wolvos TA. Advanced wound care with stable, super-oxidized water: A look at how combination therapy can optimize wound healing. Comp Cli Res Pract 2006; 18(1): 11-3.
[135]
Martinez-De Jesus FR, Ramos-De la Medina A, Remes-Troche JM, et al. Efficacy and safety of neutral pH superoxidised solution in severe diabetic foot infections. Int Wound J 2007; 4(4): 353-62.
[136]
Paola LD, Brocco E, Senesi A, et al. Super-oxidized solution (sos) therapy for infected diabetic foot ulcers. Wounds: Comp Cli Res Pract 2006; 18(9): 262-70.
[137]
Rosenkranz HSRS. Silver Sulfadiazine: Interaction with Isolated Deoxyribonucleic Acid. Anti Age Chem 1972; 2(5): 273-383.
[138]
Wood JFAF. Effects of silver on wound management. Wounds: Comp Cli Res Pract 2001; 13: 4.
[139]
Yin HQ, Langford R, Burrell RE. Comparative evaluation of the antimicrobial activity of ACTICOAT antimicrobial barrier dressing. J Burn Care Res 1999; 20(3): 195-200.
[140]
Tian J, Wong KK, Ho CM, et al. Topical delivery of silver nanoparticles promotes wound healing. ChemMedChem 2007; 2(1): 129-36.
[141]
Kajita M, Hikosaka K, Iitsuka M, Kanayama A, Toshima N, Miyamoto Y. Platinum nanoparticle is a useful scavenger of superoxide anion and hydrogen peroxide. Free Radic Res 2007; 41(6): 615-26.
[142]
Neal AL. What can be inferred from bacterium-nanoparticle interactions about the potential consequences of environmental exposure to nanoparticles? Ecot J 2008; 17(5): 362-71.
[143]
Burd A, Kwok CH, Hung SC, et al. A comparative study of the cytotoxicity of silver-based dressings in monolayer cell, tissue explant, and animal models. Wound Repair Regen 2007; 15(1): 94-104.
[144]
Duc Q, Breetveld M, Middelkoop E, Scheper RJ, Ulrich MM, Gibbs S. A cytotoxic analysis of antiseptic medication on skin substitutes and autograft. Br J Dermatol 2007; 157(1): 33-40.
[145]
Becker S, Soukup JM, Gallagher JE. Differential particulate air pollution induced oxidant stress in human granulocytes, monocytes and alveolar macrophages. Toxicol In Vitro 2002; 16(3): 209-18.
[146]
Leu JG, Chen SA, Chen HM, et al. The effects of gold nanoparticles in wound healing with antioxidant epigallocatechin gallate and alpha-lipoic acid. Nan Nanotec Bio Med 2012; 8(5): 767-75.
[147]
Zheng D, Giljohann DA, Chen DL, et al. Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation. Nat Acad Sci USA 2012; 109(30): 11975-80.
[148]
Sen CK. Wound healing essentials: let there be oxygen. Wound Repair Regen 2009; 17(1): 1-18.
[149]
Gennari MS, de Oliveira MG. Nitric oxide-releasing hydrogels for increasing dermal blood flow: Concentration and diffusion effects. NOJ 2008; 19: 40-6.
[150]
Seabra AB, Fitzpatrick A, Paul J, De Oliveira MG, Weller R. Topically applied S-nitrosothiol-containing hydrogels as experimental and pharmacological nitric oxide donors in human skin. Br J Dermatol 2004; 151(5): 977-83.
[151]
Milena T. Pelegrino LCS, Carolina M. Watashi, Paula S. Haddad, Tiago Rodrigues, Amedea B. Seabra. Nitric oxide-releasing nanoparticles: synthesis, characterization, and cytotoxicity to tumorigenic cells. J Nano Res 2017; 19: 57.
[152]
PKafshgari MH, Cavallaro A, Delalat B, et al. Nitric oxide-releasing porous silicon nanoparticles. Nano Res let 2014; 9(1): 333.
[153]
Han G, Nguyen LN, Macherla C, et al. Nitric oxide-releasing nanoparticles accelerate wound healing by promoting fibroblast migration and collagen deposition. Ame J Pat 2012; 180(4): 1465-73.
[154]
Ryter SW, Kim HP, Hoetzel A, et al. Mechanisms of cell death in oxidative stress. Antio Red Sig 2007; 9(1): 49-89.
[155]
Shen C, James SA, de Jonge MD, Turney TW, Wright PF, Feltis BN. Relating cytotoxicity, zinc ions, and reactive oxygen in ZnO nanoparticle-exposed human immune cells. J Soc Toxic 2013; 136(1): 120-30.
[156]
Alkaladi A, Abdelazim AM, Afifi M. Antidiabetic activity of zinc oxide and silver nanoparticles on streptozotocin-induced diabetic rats. Int J Mol Sci 2014; 15(2): 2015-23.
[157]
Ali NazarizadehEmail author, Asri-Rezaie S. Comparative study of antidiabetic activity and oxidative stress induced by zinc oxide nanoparticles and zinc sulfate in diabetic rats. AAPS PharmSciTech 2016; 17(4): 834-43.
[158]
Umrani RD, Paknikar KM. Zinc oxide nanoparticles show antidiabetic activity in streptozotocin-induced Type 1 and 2 diabetic rats. Nano J 2014; 9(1): 89-104.
[159]
Hackenberg S, Kleinsasser N. Dermal toxicity of ZnO nanoparticles: A worrying feature of sunscreen? Nanomed 2012; 7(4): 461-3.
[160]
Hinman CD, Maibach H. Effect of air exposure and occlusion on experimental human skin wounds. Natl J 1963; 200: 377-8.
[161]
Abrigo M, McArthur SL, Kingshott P. Electrospun nanofibers as dressings for chronic wound care: advances, challenges, and future prospects. Macr Bios 2014; 14(6): 772-92.
[162]
Murugan R, Ramakrishna S. Nano-featured scaffolds for tissue engineering: a review of spinning methodologies. Tissue Eng 2006; 12(3): 435-47.
[163]
Lowe A, Bills J, Verma R, Lavery L, Davis K, Balkus KJ Jr. Electrospun nitric oxide releasing bandage with enhanced wound healing. Acta Biomed 2015; 13: 121-30.
[164]
Zhang Y, Lim CT, Ramakrishna S, Huang ZM. Recent development of polymer nanofibers for biomedical and biotechnological applications. J Mater Sci Mater Med 2005; 16(10): 933-46.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 1
Year: 2019
Page: [2 - 14]
Pages: 13
DOI: 10.2174/1573399813666170519102406
Price: $65

Article Metrics

PDF: 60
HTML: 10
PRC: 2